2008 Clinical Practice Guidelines - Canadian Diabetes Association
2008 Clinical Practice Guidelines - Canadian Diabetes Association
2008 Clinical Practice Guidelines - Canadian Diabetes Association
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>2008</strong> CLINICAL PRACTICE GUIDELINES<br />
S108<br />
highly motivated individuals with hypercholesterolemia but<br />
without diabetes (8). However, in a “real-world” setting, only<br />
one-third of individuals were able to adhere to this diet over<br />
a 1-year period of time (9). Regular aerobic exercise helps<br />
individuals lose weight and maintain this weight reduction<br />
over time (10), and may be associated with reductions in TG<br />
and elevations in HDL-C. Regular exercise can also improve<br />
glycemic control in people with type 2 diabetes (11) and is<br />
associated with substantial reductions in CV morbidity and<br />
mortality in both type 1 (12) and type 2 diabetes (13-15).<br />
Indeed, a steep inverse relationship between fitness and mortality<br />
was observed in a cohort of men with diabetes, and this<br />
association was independent of BMI (16). Smoking cessation<br />
should be encouraged and supported.While lifestyle modification<br />
should be encouraged in all people with dyslipidemia,<br />
most will be unable to achieve recommended lipid targets<br />
without pharmacologic intervention. Accordingly, for most<br />
people with diabetes, lifestyle interventions should be seen<br />
as an important adjunct to, but not a substitute for, pharmacologic<br />
treatment.<br />
LDL-C<br />
A number of studies have shown that the degree of LDL-C<br />
lowering with statins and the beneficial effects of lowering<br />
LDL-C apply equally well to people with and without diabetes<br />
(17-24). Large, recently published trials have demonstrated<br />
the benefits of statin therapy in both the primary and<br />
secondary prevention of vascular disease, and subgroup<br />
analyses of these studies have shown similar benefits in subsets<br />
of participants with diabetes (17-19).While statin therapy<br />
across all subgroups has shown the same relative risk<br />
reduction in terms of outcomes, the absolute benefit<br />
depends on absolute risk, which is increased in people with<br />
diabetes. Subgroup analyses from statin trials have also<br />
shown similar benefits of LDL-C lowering, regardless of<br />
baseline LDL-C (20,22). Therefore, statin use should be<br />
considered for any person with diabetes at high risk of a vascular<br />
event. In the very small group of lower-risk individuals<br />
with type 2 diabetes, the relative reduction in CVD risk<br />
with statin therapy is likely to be similar to those at higher<br />
global risk for CVD, but the absolute benefit from statin<br />
therapy is predicted to be small. However, such individuals’<br />
global CVD risk will increase with age and in the presence<br />
of additional risk factors for CVD.Therefore, repeated monitoring<br />
of the individual’s clinical condition and lipid screening<br />
every 1 to 3 years, as outlined in the Screening section<br />
above, are recommended.<br />
The results of the Heart Protection Study (HPS) provide<br />
considerable insight into the importance of LDL-C lowering<br />
(21). In this large study involving >20 000 subjects, a similar<br />
benefit in terms of risk ratio reduction was observed in subjects<br />
with baseline LDL-C >3.5 mmol/L, 3.0 to 3.5 mmol/L<br />
and